Heterobicyclic inhibitors of transforming growth factor beta receptor I (TGF beta RI).
Harikrishnan, L.S., Warrier, J., Tebben, A.J., Tonukunuru, G., Madduri, S.R., Baligar, V., Mannoori, R., Seshadri, B., Rahaman, H., Arunachalam, P.N., Dikundwar, A.G., Fink, B.E., Fargnoli, J., Fereshteh, M., Fan, Y., Lippy, J., Ho, C.P., Wautlet, B., Sheriff, S., Ruzanov, M., Borzilleri, R.M.(2018) Bioorg Med Chem 26: 1026-1034
- PubMed: 29422332 
- DOI: 10.1016/j.bmc.2018.01.014
- Primary Citation of Related Structures:  
6B8Y - PubMed Abstract: 
The TGFβ-TGFβR signaling pathway has been reported to play a protective role in the later stages of tumorigenesis via increasing immunosuppressive Treg cells and facilitating the epithelial to mesenchymal transition (EMT). Therefore, inhibition of TGFβR has the potential to enhance antitumor immunity ...